Page last updated: 2024-10-21

edelfosine and Angiogenesis, Pathologic

edelfosine has been researched along with Angiogenesis, Pathologic in 2 studies

edelfosine: RN given refers to parent cpd
edelfosine : A racemate comprising equimolar amounts of (R)- and (S)-edelfosine.
1-octadecyl-2-methylglycero-3-phosphocholine : A glycerophosphocholine that is glycero-3-phosphocholine substituted at positions 1 and 2 by octadecyl and methyl groups respectively.

Research Excerpts

ExcerptRelevanceReference
"Edelfosine is an alkyl-lysophospholipid that acts as an anticancer agent in vivo."1.30The anticancer drug edelfosine is a potent inhibitor of neovascularization in vivo. ( Ades, EW; Bouck, N; Liu, J; Vogler, WR; Volpert, O, 1998)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Candal, FJ1
Bosse, DC1
Vogler, WR2
Ades, EW2
Liu, J1
Volpert, O1
Bouck, N1

Other Studies

2 other studies available for edelfosine and Angiogenesis, Pathologic

ArticleYear
Inhibition of induced angiogenesis in a human microvascular endothelial cell line by ET-18-OCH3.
    Cancer chemotherapy and pharmacology, 1994, Volume: 34, Issue:2

    Topics: Antineoplastic Agents; Cell Adhesion Molecules; Depression, Chemical; Dose-Response Relationship, Dr

1994
The anticancer drug edelfosine is a potent inhibitor of neovascularization in vivo.
    Cancer investigation, 1998, Volume: 16, Issue:8

    Topics: Animals; Antineoplastic Agents; Cattle; Cell Movement; Cells, Cultured; Cornea; Endothelium, Vascula

1998